BACKGROUND Breast cancer is one of the most common malignant tumors in women worldwide and poses a severe threat to their health.Therefore,this study examined patients who underwent breast cancer surgery,analyzed hosp...BACKGROUND Breast cancer is one of the most common malignant tumors in women worldwide and poses a severe threat to their health.Therefore,this study examined patients who underwent breast cancer surgery,analyzed hospitalization costs and structure,and explored the impact of China Healthcare Security Diagnosis Related Groups(CHS-DRG)management on patient costs.It aimed to provide medical institutions with ways to reduce costs,optimize cost structures,reduce patient burden,and improve service efficiency.AIM To study the CHS-DRG payment system’s impact on breast cancer surgery costs.METHODS Using the CHS-DRG(version 1.1)grouping criteria,4073 patients,who underwent the radical resection of breast malignant tumors from January to December 2023,were included in the JA29 group;1028 patients were part of the CHS-DRG payment system,unlike the rest.Through an independent sample t-test,the length of hospital stay as well as total hospitalization,medicine and consumables,medical,nursing,medical technology,and management expenses were compared.Pearson’s correlation coefficient was used to test the cost correlation.RESULTS In terms of hospitalization expenses,patients in the CHS-DRG payment group had lower medical,nursing,and management expenses than those in the diagnosis-related group(DRG)non-payment group.For patients in the DRG payment group,the factors affecting the total hospitalization cost,in descending order of relevance,were medicine and consumable costs,consumable costs,medicine costs,medical costs,medical technology costs,management costs,nursing costs,and length of hospital stay.For patients in the DRG nonpayment group,the factors affecting the total hospitalization expenses in descending order of relevance were medicines and consumable expenses,consumable expenses,medical technology expenses,the cost of medicines,medical expenses,nursing expenses,length of hospital stay,and management expenses.CONCLUSION The CHS-DRG system can help control and reduce unnecessary medical expenses by controlling medicine costs,medical consumable costs,and the length of hospital stay while ensuring medical safety.展开更多
目的比较分析实施疾病诊断相关分组(diagnosis related group,DRG)支付方式改革地区的基础病组同病同价支付政策,为该政策的优化与推广提供参考建议。方法检索全国省级医疗保障局网站和190个实施DRG支付方式改革城市的医疗保障局网站,收...目的比较分析实施疾病诊断相关分组(diagnosis related group,DRG)支付方式改革地区的基础病组同病同价支付政策,为该政策的优化与推广提供参考建议。方法检索全国省级医疗保障局网站和190个实施DRG支付方式改革城市的医疗保障局网站,收集2019年1月1日—2024年5月31日其官网发布的DRG政策文件,应用Excel软件整理资料,采用比较分析法归纳总结基础病组政策的地区覆盖、医疗机构覆盖和病组覆盖现状。结果DRG基础病组同病同价支付政策覆盖地区数量少且不均衡,共16个省、2个直辖市及3个自治区的76个地市实施了该政策,占实施DRG付费城市总数的40%,且主要集中于东部地区。医疗机构覆盖面存在差异,大部分地区的基础病组政策覆盖所有级别的医疗机构,部分地区的基础病组政策主要在二级和三级医疗机构实施。病组遴选标准基本一致,以常见、多发,诊疗技术成熟、难度低和医疗费用稳定且差异小为主要纳入标准。地区间基础病组数量、权重和分布不均衡,纳入的基础病组数量为3~117不等,权重区间为0.16~1.57,以内科治疗为主,哮喘和高血压是最常见的基础病组。结论建议进一步扩展DRG基础病组同病同价支付政策覆盖的地区范围,因地制宜确定医疗机构覆盖范围,分阶段扩展病种覆盖范围,加强政策实施效果评价。展开更多
目的基于疾病诊断相关组(DRG)比较分析医院感染患者的经济负担情况,为医院感染防控提供支持。方法采用回顾性分析方法分析某院2018—2020年住院患者医院感染病例的住院日数及医疗费用,并与DRG同组患者的住院日数及费用等进行比较。结果2...目的基于疾病诊断相关组(DRG)比较分析医院感染患者的经济负担情况,为医院感染防控提供支持。方法采用回顾性分析方法分析某院2018—2020年住院患者医院感染病例的住院日数及医疗费用,并与DRG同组患者的住院日数及费用等进行比较。结果2018—2020年医院感染病例数分别为694、1102、819例次,同期DRG分组病例数分别为72707、92837、59398例次;各年份医院感染患者的平均住院日均高于DRG同组患者(31.07 d VS 13.05 d,65.98 d VS 47.51 d,35.38 d VS 13.45 d),差异均有统计学意义(均P<0.01);各年份医院感染患者的平均住院费用均高于DRG同组患者(12.29万元VS 3.84万元,17.18万元VS 4.12万元,15.75万元VS 4.43万元),差异均有统计学意义(均P<0.01)。从感染部位来看,导管相关血流感染的平均住院费用最高,2018—2020年各年份分别为22.57、35.88、26.80万元。导管相关血流感染患者的三年平均住院日数为102.00 d、住院费用为28.42万元,较之DRG同组患者的平均住院日数及费用分别增加88.78 d、24.27万元。结论住院患者发生医院感染将显著增加患者的直接经济负担,控制导管相关血流感染是减轻医院感染经济负担的重中之重,在DRG支付方式下,做好医院感染预防与控制势在必行。展开更多
基金Research Center for Capital Health Management and Policy,No.2024JD09.
文摘BACKGROUND Breast cancer is one of the most common malignant tumors in women worldwide and poses a severe threat to their health.Therefore,this study examined patients who underwent breast cancer surgery,analyzed hospitalization costs and structure,and explored the impact of China Healthcare Security Diagnosis Related Groups(CHS-DRG)management on patient costs.It aimed to provide medical institutions with ways to reduce costs,optimize cost structures,reduce patient burden,and improve service efficiency.AIM To study the CHS-DRG payment system’s impact on breast cancer surgery costs.METHODS Using the CHS-DRG(version 1.1)grouping criteria,4073 patients,who underwent the radical resection of breast malignant tumors from January to December 2023,were included in the JA29 group;1028 patients were part of the CHS-DRG payment system,unlike the rest.Through an independent sample t-test,the length of hospital stay as well as total hospitalization,medicine and consumables,medical,nursing,medical technology,and management expenses were compared.Pearson’s correlation coefficient was used to test the cost correlation.RESULTS In terms of hospitalization expenses,patients in the CHS-DRG payment group had lower medical,nursing,and management expenses than those in the diagnosis-related group(DRG)non-payment group.For patients in the DRG payment group,the factors affecting the total hospitalization cost,in descending order of relevance,were medicine and consumable costs,consumable costs,medicine costs,medical costs,medical technology costs,management costs,nursing costs,and length of hospital stay.For patients in the DRG nonpayment group,the factors affecting the total hospitalization expenses in descending order of relevance were medicines and consumable expenses,consumable expenses,medical technology expenses,the cost of medicines,medical expenses,nursing expenses,length of hospital stay,and management expenses.CONCLUSION The CHS-DRG system can help control and reduce unnecessary medical expenses by controlling medicine costs,medical consumable costs,and the length of hospital stay while ensuring medical safety.
文摘目的比较分析实施疾病诊断相关分组(diagnosis related group,DRG)支付方式改革地区的基础病组同病同价支付政策,为该政策的优化与推广提供参考建议。方法检索全国省级医疗保障局网站和190个实施DRG支付方式改革城市的医疗保障局网站,收集2019年1月1日—2024年5月31日其官网发布的DRG政策文件,应用Excel软件整理资料,采用比较分析法归纳总结基础病组政策的地区覆盖、医疗机构覆盖和病组覆盖现状。结果DRG基础病组同病同价支付政策覆盖地区数量少且不均衡,共16个省、2个直辖市及3个自治区的76个地市实施了该政策,占实施DRG付费城市总数的40%,且主要集中于东部地区。医疗机构覆盖面存在差异,大部分地区的基础病组政策覆盖所有级别的医疗机构,部分地区的基础病组政策主要在二级和三级医疗机构实施。病组遴选标准基本一致,以常见、多发,诊疗技术成熟、难度低和医疗费用稳定且差异小为主要纳入标准。地区间基础病组数量、权重和分布不均衡,纳入的基础病组数量为3~117不等,权重区间为0.16~1.57,以内科治疗为主,哮喘和高血压是最常见的基础病组。结论建议进一步扩展DRG基础病组同病同价支付政策覆盖的地区范围,因地制宜确定医疗机构覆盖范围,分阶段扩展病种覆盖范围,加强政策实施效果评价。
文摘目的基于疾病诊断相关组(DRG)比较分析医院感染患者的经济负担情况,为医院感染防控提供支持。方法采用回顾性分析方法分析某院2018—2020年住院患者医院感染病例的住院日数及医疗费用,并与DRG同组患者的住院日数及费用等进行比较。结果2018—2020年医院感染病例数分别为694、1102、819例次,同期DRG分组病例数分别为72707、92837、59398例次;各年份医院感染患者的平均住院日均高于DRG同组患者(31.07 d VS 13.05 d,65.98 d VS 47.51 d,35.38 d VS 13.45 d),差异均有统计学意义(均P<0.01);各年份医院感染患者的平均住院费用均高于DRG同组患者(12.29万元VS 3.84万元,17.18万元VS 4.12万元,15.75万元VS 4.43万元),差异均有统计学意义(均P<0.01)。从感染部位来看,导管相关血流感染的平均住院费用最高,2018—2020年各年份分别为22.57、35.88、26.80万元。导管相关血流感染患者的三年平均住院日数为102.00 d、住院费用为28.42万元,较之DRG同组患者的平均住院日数及费用分别增加88.78 d、24.27万元。结论住院患者发生医院感染将显著增加患者的直接经济负担,控制导管相关血流感染是减轻医院感染经济负担的重中之重,在DRG支付方式下,做好医院感染预防与控制势在必行。
